This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia (NF1TD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Shriners Hospitals for Children.
Recruitment status was:  Recruiting
University of Utah
Information provided by:
Shriners Hospitals for Children Identifier:
First received: March 14, 2006
Last updated: May 20, 2008
Last verified: May 2008
The study is a multicenter four-year outcome study of the natural history of tibial dysplasia in patients with NF1 and selected patients without NF1. We will obtain information on the natural history, burden, functional and health status, health-related quality of life, and surgical interventions/outcomes of tibial dysplasia. The project will also establish a Core Facility (NOCF) for tissue samples for future studies.

Neurofibromatosis Type 1 Tibial Dysplasia

Study Type: Observational
Official Title: Multicenter Study of Tibial Dysplasia in Neurofibromatosis Type I (NF1) Patients

Resource links provided by NLM:

Further study details as provided by Shriners Hospitals for Children:

Biospecimen Retention:   Samples With DNA
If the enrollee's private physician includes surgery in the management of his/her disorder, and if tissue is removed to be discarded, permission is obtained to store the specimen in a tissue repository for future research.

Estimated Enrollment: 420
Study Start Date: March 2004
Estimated Study Completion Date: December 2008
Detailed Description:

The three specific aims of this study are:

  • Specific Aim 1 - To assess health status and health - related quality of life (HRQL) in 50 children and adolescents with NF1 and tibial dysplasia and in NF1 controls. We hypothesize that children and adolescents with NF1 and tibial dysplasia will experience an additional burden of morbidity due to tibial dysplasia and a downward trajectory of health status and HRQL over time.
  • Specific Aim 2 - To assess the long term outcome of current treatment in 100 adult patients diagnosed with NF1 and tibial dysplasia in childhood. We hypothesize that better quality of life and function, in adults with NF1 and tibial dysplasia, are associated with amputation in childhood compared to multiple surgical procedures, the lack of fibular involvement, and fracture later in childhood. We also hypothesize that individuals with NF1 and tibial dysplasia have a higher risk of other bony dysplasias but are at no higher risk of fracture in other bones.
  • Specific Aim 3 - To assess the natural history and short-term response to therapy in a cohort of at least 60 children with NF1 and tibial dysplasia and at least 60 children with tibial dysplasia presumably without NF1 prospectively diagnosed during the course of the four-year study period. We hypothesize that NF1 patients with earlier presentation, Crawford Class II A-C, male gender, and the lack of bracing prior to age two are more likely to fracture. We also postulate that individuals with and without NF1 have a similar outcome and response to treatment.

The results of this project will provide a rational basis for future clinical and therapeutic trials.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults and children with NF1, with or without Tibial Dysplasia, ages 3+ and individuals ages birth through 18 with Tibial Dysplasia, with or without NF1.

Inclusion Criteria:

  • Aim 1:

    • Group 1, NF1 with Tibial Dysplasia, Ages: 3-18
    • Group 2 (control), NF1 without Tibial Dysplasia, Ages 3-18
  • Aim 2: NF1 with Tibial Dysplasia, 19+
  • Aim 3: Tibial Dysplasia with or without NF1, Ages: birth to 18
  • Tissue procurement, any participant undergoing surgery at the tibial site for routine standard of care

Exclusion Criteria:

  • Patients without a diagnosis of NF1 or Tibial Dysplasia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00303368

Contact: Jeanne A Siebert, MBA 801-536-3601
Contact: Susan J Geyer, BA 801-536-3561

United States, Utah
Shriners Hospitals for Children, Intermountain Hospital Recruiting
Salt Lake City, Utah, United States, 84103
Contact: Jeanne A Siebert, MBA    801-536-3601   
Contact: Susan J Geyer, BA    801-536-3561   
Principal Investigator: Jacques D'Astous, MD         
Sponsors and Collaborators
Shriners Hospitals for Children
University of Utah
Principal Investigator: John C Carey, MD, MPH University of Utah, Health Science Center
  More Information

Responsible Party: John C. Carey, MD, Shriners Hospitals for Children Identifier: NCT00303368     History of Changes
Other Study ID Numbers: 9165
Study First Received: March 14, 2006
Last Updated: May 20, 2008

Keywords provided by Shriners Hospitals for Children:
Neurofibromatosis (NF1)
Tibial Dysplasia (TD)

Additional relevant MeSH terms:
Neurofibromatosis 1
Pathologic Processes
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Peripheral Nervous System Neoplasms
Nervous System Neoplasms
Peripheral Nervous System Diseases
Neuromuscular Diseases processed this record on September 21, 2017